about
Hydrogels in spinal cord injury repair strategies3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors.Mutant prion protein expression is associated with an alteration of the Rab GDP dissociation inhibitor alpha (GDI)/Rab11 pathwayBone marrow mesenchymal stromal cells drive protective M2 microglia polarization after brain traumaIntracerebroventricular administration of human umbilical cord blood cells delays disease progression in two murine models of motor neuron degeneration.The toxicity of a mutant prion protein is cell-autonomous, and can be suppressed by wild-type prion protein on adjacent cells.Tunable hydrogel-nanoparticles release system for sustained combination therapies in the spinal cord.Functional alterations of the ubiquitin-proteasome system in motor neurons of a mouse model of familial amyotrophic lateral sclerosisNeuroprotective effects of toll-like receptor 4 antagonism in spinal cord cultures and in a mouse model of motor neuron degeneration.Nanovector-mediated drug delivery for spinal cord injury treatment.Modulators of microglia: a patent review.Non-invasive in vitro and in vivo monitoring of degradation of fluorescently labeled hyaluronan hydrogels for tissue engineering applications.Novel functionalization strategies to improve drug delivery from polymers.A new fluorogenic peptide determines proteasome activity in single cells.Amyotrophic Lateral Sclerosis, a Multisystem Pathology: Insights into the Role of TNFα.Characterization and degradation behavior of agar-carbomer based hydrogels for drug delivery applications: solute effect.Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus.Polymeric nanoparticle system to target activated microglia/macrophages in spinal cord injury.Activation of the p38MAPK cascade is associated with upregulation of TNF alpha receptors in the spinal motor neurons of mouse models of familial ALS.Persistent activation of p38 mitogen-activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates with disease progression.Selective nanovector mediated treatment of activated proinflammatory microglia/macrophages in spinal cord injury.Specific inhibition of the JNK pathway promotes locomotor recovery and neuroprotection after mouse spinal cord injury.Ranolazine ameliorates postresuscitation electrical instability and myocardial dysfunction and improves survival with good neurologic recovery in a rat model of cardiac arrest.Microwave-assisted synthesis of TEMPO-labeled hydrogels traceable with MRI.A new three dimensional biomimetic hydrogel to deliver factors secreted by human mesenchymal stem cells in spinal cord injury.Soluble Aβ oligomer-induced synaptopathy: c-Jun N-terminal kinase's role.Current Options for Cell Therapy in Spinal Cord Injury.Mesenchymal stem cells encapsulated into biomimetic hydrogel scaffold gradually release CCL2 chemokine in situ preserving cytoarchitecture and promoting functional recovery in spinal cord injury.Multiple drug delivery hydrogel system for spinal cord injury repair strategiesEarly modulation of pro-inflammatory microglia by minocycline loaded nanoparticles confers long lasting protection after spinal cord injuryIn situ agar–carbomer hydrogel polycondensation: A chemical approach to regenerative medicineDistribution and cellular localization of high mobility group box protein 1 (HMGB1) in the spinal cord of a transgenic mouse model of ALSSelective Modulation of A1 Astrocytes by Drug-Loaded Nano-Structured Gel in Spinal Cord Injury
P50
Q26852732-BFCE1105-7F41-4ADB-BB3A-56DC8E7A69C3Q30828511-1ECD7553-AA37-45C8-B992-3DEAF3DEC60EQ33812876-821CCB7D-DA0E-44AA-B5AF-0B3BE6878D32Q34000812-8968BD6B-D5EC-49F6-8E07-D42C52376815Q34041845-F610169B-C841-4E57-A57F-ADA140E9EB50Q34200990-20EB3B5C-3FED-4143-9EE6-3D9BB5142C94Q34641070-5A32F14D-5918-4370-8B66-6EFD3C49ADB8Q35819865-4BC61AE0-B2FD-4503-9455-3D66ED144242Q36283426-4139A470-33D7-4950-9CFA-B44B69F6C897Q38213218-AB881AE7-58A1-412C-B5A3-A6ED3D6F8823Q38685760-00FF0091-F2DA-45B4-9C73-5EFFC5B62260Q38936963-DE9D6723-E384-471D-8161-28257E3D995DQ39095290-A3C4EAD5-E3B9-4564-907F-FD3A38B6081BQ39649696-13132966-7B2F-4A49-BEEB-DFB0BFF02D2CQ42730558-FD7DFD0C-8767-42D9-BC0A-BEC349939532Q42790049-F5D8F5A7-1684-400E-878D-ACD337ADF54AQ44814719-A4BD1A78-8121-4304-AA94-95FAACB01D97Q45391695-100253FE-4DE2-404B-9D0B-477C0155AC1CQ46541571-4A46A972-12BC-43BD-8059-126FE95A3774Q47822839-63E78EEE-6EC7-4BC9-8521-571A7C3E79C9Q48412289-94A89EB2-025D-4516-B546-E4A08CDA9FAEQ48610213-F5587A2B-214E-455C-8C63-DE2F3194E491Q48770283-95242C29-7B6E-431F-A8C1-1947A9B63323Q50048843-08AE9BC7-A51F-449B-B63E-7C4CE7696D1CQ50920491-D49E6DE5-9F16-4625-91C3-8EF046DD5716Q51053544-C5DA1134-59BA-4574-940B-5AA670828493Q51807293-8E82EB44-2EF1-4522-9A25-F6D311DA389FQ52330870-EC80AFC8-DD8D-4028-91B0-00D8B179EB94Q57184324-4481FFB6-9EDE-4CFE-B81A-4D56A107EED0Q57716328-058DD0B0-D853-462A-9176-347562E6E5BAQ57716376-93DF338A-7400-4DC3-A114-DA2337B0B4BEQ57716389-4F454BC5-6808-4F93-9CC1-7EAF9482D3C9Q92319407-02AB4CA3-7A63-476D-B142-ACD5CDA1D97B
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
P Veglianese
@ast
P Veglianese
@en
P Veglianese
@es
P Veglianese
@nl
type
label
P Veglianese
@ast
P Veglianese
@en
P Veglianese
@es
P Veglianese
@nl
prefLabel
P Veglianese
@ast
P Veglianese
@en
P Veglianese
@es
P Veglianese
@nl
P106
P1153
15756380100
P31
P496
0000-0002-0183-9428